Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ZAI LAB LTD : Change in Directors or Principal Officers (form 8-K)

08/03/2022 | 04:13pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

As previously announced, Zai Lab Limited (the "Company") appointed Joshua Smiley as the Company's Chief Operating Officer, effective on August 1, 2022, following the completion of his leave with his former employer. Mr. Smiley, aged 53, began his career at Eli Lilly and Company in 1995 holding leadership positions across the organization, including serving as Senior Vice President and Chief Financial Officer. Mr. Smiley earned his bachelor's degree in history from Harvard College in 1993.

In connection with Mr. Smiley's appointment, Zai Lab (US) LLC, a wholly owned subsidiary of the Company, entered into a written employment agreement (the "Agreement") with Mr. Smiley. The Agreement provides Mr. Smiley with an annual base salary of $600,000 per year, pro-rated for his period of service as Chief Operating Officer in 2022. Mr. Smiley is also eligible to participate in our annual bonus program, with a target annual bonus opportunity of 50% of his base salary. The actual bonus award amounts will be determined by the Board of Directors of the Company (or the Compensation Committee thereof) based on Mr. Smiley's performance and the Company's performance against goals established by the Board of Directors (or the Compensation Committee thereof). In addition, the Agreement provides Mr. Smiley with a cash sign-on bonus of $400,000 to be paid in two installments: $250,000 in August 2022 and $150,000 in August 2023, with the second installment contingent upon Mr. Smiley relocating to the Boston area by such time. The Company will also grant to Mr. Smiley in August 2022 an option to purchase up to 139,000 American Depositary Shares of the Company ("ADSs") with an exercise price per share equal to the fair market value of an ADS on the date of the grant (the "Option") and restricted share units representing 79,500 ADSs (the "Restricted Share Units"), each under and subject to the terms and conditions of the Zai Lab Limited 2022 Equity Incentive Plan (the "Plan"). The Option and Restricted Share Units will each vest annually over five years, subject to the terms of the Plan and the applicable Option and Restricted Share Unit agreements and Mr. Smiley's continued employment with the Company.

In accordance with the Company's customary practice, the Company has entered into an indemnification agreement with Mr. Smiley, which requires the Company to indemnify Mr. Smiley against certain liabilities that may arise in connection with his status or service as an executive officer.

The foregoing description of the indemnification agreement does not purport to be complete and is qualified in its entirety by the full text of the form of indemnification agreement, which is filed as Exhibit 10.25 to the Company's Annual Report on Form 10-K filed on March 1, 2022 and which is incorporated herein by reference.

There are no arrangements or understandings between Mr. Smiley and any other person pursuant to which he was appointed as Chief Operating Officer, nor are there any transactions between Mr. Smiley and the Company that would be reportable under Item 404(a) of Regulation S-K. There are no family relationships between Mr. Smiley and any of our directors or executive officers.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ZAI LAB LIMITED
09/21Asian ADRs Move Lower in Wednesday Trading
MT
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance..
GL
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance..
AQ
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® Maintenance Treatment i..
CI
09/12DRI Healthcare Trust Acquires Royalty Interest in Zejula, Currently Approved for Treatm..
MT
09/09Asian ADRs Climb Sharply Higher in Friday Trading
MT
09/08TRANSCRIPT : Zai Lab Limited Presents at Citi's 17th Annual BioPharma Conference, Sep-08-2..
CI
08/29US, China Reach Audit Deal to Prevent Delistings
MT
08/26ZAI LAB : Updated Statement on SEC Listing Matter
PU
08/23Zai Lab Announces Participation in September Investor Conferences
GL
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 215 M - -
Net income 2022 -481 M - -
Net cash 2022 799 M - -
P/E ratio 2022 -8,24x
Yield 2022 -
Capitalization 3 546 M 3 546 M -
EV / Sales 2022 12,8x
EV / Sales 2023 6,22x
Nbr of Employees 1 951
Free-Float 99,8%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 37,00 $
Average target price 97,22 $
Spread / Average Target 163%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Joshua L. Smiley Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-41.13%3 546
CSL LIMITED-4.33%87 783
SAMSUNG BIOLOGICS CO.,LTD.-14.73%38 653
BIOGEN INC.-17.56%28 700
WUXI BIOLOGICS (CAYMAN) INC.-49.86%25 210
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-31.77%19 085